Move to topTop
January 26, 2021

Terumo Aortic announced today the completion of enrolment of the Relay™Pro Traumatic Injury (RelayPro-T) Investigational Device Exemption (IDE) study in the United States. RelayPro is a low profile, next generation thoracic stent graft device designed to expand the treatment of thoracic endovascular aortic repair (TEVAR) to patients with smaller access vessels.

The RelayPro-T study has successfully enrolled a total of 50 patients with traumatic injury of the descending thoracic aorta at 16 sites across the United States.

The purpose of this prospective, multicentre, non-blinded, non-randomised study is to analyse endovascular repair of traumatic aortic injury, or transection, usually caused by high speed impacts such as those in road traffic accidents or serious falls. The primary endpoint of the trial is all-cause mortality at 30 days with follow-up continuing for five years.

Co-National Principal Investigator, Benjamin W Starnes, MD, (Professor of Vascular Surgery, Chief of Division of Vascular Surgery and Vice Chair of Department of Surgery, University of Washington, Seattle, US) commented: "This is an important landmark in moving this device along the regulatory pathway and making it available to surgeons throughout the United States to treat these emergency cases. The Relay device has already shown outstanding navigability, total accuracy, and less risk of air embolism thanks to its unique dual sheath design. In addition, the low profile of the Relay®Pro device will make it suitable for more patients."

Furthermore, co-National Principal Investigator, Ravi Rajani, MD, (Associate Professor of Vascular Surgery, Emory University School of Medicine and Chief of Vascular and Endovascular Surgery, Grady Memorial Hospital, Atlanta, US) added: "The endovascular management of traumatic aortic injury has the potential advantages of less morbidity due to smaller incisions as well as shorter operating times. A device that can further improve on these advantages with a lower profile and a more flexible delivery system will be a welcome addition to our treatment options. Greater spacing between stent zones makes it more conformable to the aortic wall, even in the highly angled aortic arch of the typically young trauma patient."

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.